UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

Expert review of anticancer therapy, 2009-04, Vol.9 (4), p.425-435

2009

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1151-1153

2023

Volltextzugriff (PDF)

Total metabolic tumor volume on 18F-fluorodeoxyglucose-positron emission tomography ([18F]-FDG-PET) scan: A potential prognostic factor in extensive-stage small cell lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8574-8574

2022

Volltextzugriff (PDF)

Low PD-1 Expression in Cytotoxic CD8 + Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Clinical cancer research, 2018-01, Vol.24 (2), p.407-419

2018

Volltextzugriff (PDF)

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1281-1287

2017

Volltextzugriff (PDF)

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

The New England journal of medicine, 2023-11, Vol.389 (20), p.1839-1850

2023

Volltextzugriff (PDF)

HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis

Human pathology, 2011-06, Vol.42 (6), p.909-910

2011

Volltextzugriff (PDF)

Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer

Cancer, 2011-05, Vol.117 (9), p.1837-1846

2011

Volltextzugriff (PDF)

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2007-2019

2023

Volltextzugriff (PDF)

The lung-immune prognostic index (LIPI) to predict early mortality among patients affected by advanced solid cancers under immune-checkpoint inhibitors treatments

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14602-e14602

2023

Volltextzugriff (PDF)

Randomized Pilot Trial of Percutaneous Posterior Tibial Nerve Stimulation Versus Medical Therapy for the Treatment of Low Anterior Resection Syndrome: One-Year Follow-up

Diseases of the colon & rectum, 2020-12, Vol.63 (12), p.1602

2020

Volltextzugriff (PDF)

Herpes simplex virus type 1 dysregulates anti-fungal defenses preventing monocyte activation and downregulating toll-like receptor-2

Microbiology and immunology, 2008-12, Vol.52 (12), p.575-584

2008

Volltextzugriff (PDF)

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Journal of clinical oncology, 2024-01, Vol.42 (2), p.180

2024

Volltextzugriff (PDF)

Abstract 3011: Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.3011-3011

2021

Volltextzugriff (PDF)

Abstract 5432: Cancer of unknown primary site-of-origin: An enigma ready to be miR-solved

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5432-5432

2020

Volltextzugriff (PDF)

The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21078-e21078

2021

Volltextzugriff (PDF)

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

Anticancer research, 2014-06, Vol.34 (6), p.3185-3188

2014

Volltextzugriff (PDF)

Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients

Clinical drug investigation, 2020-03, Vol.40 (3), p.211-226

2020

Volltextzugriff (PDF)

Abstract 5361: Isolation and genetic characterization of circulating tumor cells from cancer of unknown primary

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5361-5361

2020

Volltextzugriff (PDF)

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter

Clinical cancer research, 2020-01, Vol.26 (2), p.518-519

2020

Volltextzugriff (PDF)

Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases

Surgery, 2018-09, Vol.164 (3), p.601-603

2018

Volltextzugriff (PDF)

Colony-stimulating factors for febrile neutropenia

The New England journal of medicine, 2013-07, Vol.369 (3), p.285

2013

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(78)
Berichte
(1)

Sprache

Englisch
(79)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(30)
Oncology
(20)
Female
(15)
Male
(13)
Middle Aged
(12)
Aged
(11)
Lung Neoplasms - Drug Therapy
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Adult
(8)
Chemotherapy
(7)
Treatment Outcome
(7)
Lung Cancer
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
General & Internal Medicine
(5)
Immunotherapy
(5)
Medicine, General & Internal
(5)
Patients
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Total metabolic tumor volume on 18F-fluorodeoxyglucose-positron emission tomography ([18F]-FDG-PET) scan: A potential prognostic factor in extensive-stage small cell lung cancer

Low PD-1 Expression in Cytotoxic CD8 + Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis

Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

The lung-immune prognostic index (LIPI) to predict early mortality among patients affected by advanced solid cancers under immune-checkpoint inhibitors treatments

Randomized Pilot Trial of Percutaneous Posterior Tibial Nerve Stimulation Versus Medical Therapy for the Treatment of Low Anterior Resection Syndrome: One-Year Follow-up

Herpes simplex virus type 1 dysregulates anti-fungal defenses preventing monocyte activation and downregulating toll-like receptor-2

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Abstract 3011: Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models

Abstract 5432: Cancer of unknown primary site-of-origin: An enigma ready to be miR-solved

The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients

Abstract 5361: Isolation and genetic characterization of circulating tumor cells from cancer of unknown primary

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter

Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases

Colony-stimulating factors for febrile neutropenia

Aktive Filter

Suchergebnisse filtern